EU completes Meridia review
EU Committee for Proprietary Medicinal Products "issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine," Abbott announces June 27. The committee reviewed the obesity drug (Meridia in the U.S.) at the request of Italian Health Ministry after the agency suspended approval of sibutramine. Abbott expects FDA to respond by the fall to a petition from Public Citizen's Health Research Group asking that Meridia be withdrawn (1"The Pink Sheet" June 17, p. 16)...
You may also be interested in...
Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002
P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.